Liu Yu-Feng, Chen Ying-Ying, He Ying-Yi, Wang Jia-Yi, Yang Jian-Ping, Zhong Shu-Ling, Jiang Nan, Zhou Pan, Jiang Hua, Zhou Jie
Program in Immunology, Zhongshan School of Medicine, Affiliated Guangzhou Women and Children's Medical Center, Guangzhou, China.
Institute of Human Virology, Sun Yat-Sen University, Guangzhou, China.
J Leukoc Biol. 2017 Aug;102(2):449-458. doi: 10.1189/jlb.5MA1116-453RR. Epub 2017 Jun 15.
Precursor B cell acute lymphoblastic leukemia (B-ALL) is a B cell-derived, malignant disorder with the highest incidence among children. In addition to the genetic abnormality, a dysregulated immune system also has an important role in the pathogenesis of B-ALL. Myeloid-derived suppressor cells (MDSCs) represent one of the key drivers in immune tolerance against tumor cells, including various solid tumors and hematologic malignancies. The role of MDSCs in B-ALL remains poorly understood. Here, we showed that the granulocytic (G)-MDSC population was significantly elevated in both the peripheral blood and BM of patients with B-ALL, when compared with age-matched healthy controls. G-MDSCs levels correlated positively with clinical therapeutic responses and B-ALL disease prognostic markers, including minimal residual disease, and the frequencies of CD20 and blast cells. The immunosuppressive function of B-ALL-derived G-MDSCs was mediated through the production of reactive oxygen species and required direct cell-cell contact, with the potential participation of STAT3 signaling. Overall, the results of our study support accumulation and activation of G-MDSCs as a novel mechanism of immune evasion of tumor cells in patients with B-ALL and may be a new therapeutic target.
前体B细胞急性淋巴细胞白血病(B-ALL)是一种源自B细胞的恶性疾病,在儿童中发病率最高。除了基因异常外,免疫系统失调在B-ALL的发病机制中也起着重要作用。髓系来源的抑制细胞(MDSCs)是对肿瘤细胞免疫耐受的关键驱动因素之一,包括各种实体瘤和血液系统恶性肿瘤。MDSCs在B-ALL中的作用仍知之甚少。在这里,我们发现与年龄匹配的健康对照相比,B-ALL患者外周血和骨髓中的粒细胞(G)-MDSC群体显著升高。G-MDSCs水平与临床治疗反应和B-ALL疾病预后标志物呈正相关,包括微小残留病以及CD20和原始细胞的频率。B-ALL来源的G-MDSCs的免疫抑制功能是通过活性氧的产生介导的,需要细胞间直接接触,STAT3信号通路可能参与其中。总体而言,我们的研究结果支持G-MDSCs的积累和激活是B-ALL患者肿瘤细胞免疫逃逸的一种新机制,可能是一个新的治疗靶点。